Company: CMND
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001213900-25-109567
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 0
---
Filed pursuant to Rule 424(b)(5)

Registration No. 333-275991

PROSPECTUS SUPPLEMENT

(To prospectus dated December 26, 2023)

<div align='center'>958,222 Common Shares

Pre-Funded Warrants to Purchase up to 2,984,143 Common Shares

CLEARMIND MEDICINE INC.</div>

We are offering pursuant to this prospectus
supplement and the accompanying prospectus (i) 958,222 common shares, no par value, or the common shares, at an offering price of $0.20
per Common Share and (ii) pre-funded warrants to purchase up to 2,984,143 Common Shares at an offering price of $0.1999 per pre-funded
warrant. Each registered pre-funded warrant will be exercisable for one Common Share at an exercise price of $0.0001 per Common Share,
will be immediately exercisable, and will not expire until fully exercised. We are also offering pursuant to this prospectus supplement
and the accompanying prospectus the Common Shares issuable upon the exercise of the pre-funded warrants.

Our Common Shares are currently traded on the
Nasdaq Capital Market, or Nasdaq, under the symbol “CMND.” On November 11, 2025, the last reported sale price of our Common
Shares on the Nasdaq was $0.31 per share.

Our Common Shares also trade on the Frankfurt
Stock Exchange, or FSE, under the symbol “CWY”. On November 12, 2025, the last reported sales price of our Common Shares on
the FSE was EUR 0.5545 (approximately $0.64) per share.

The highest aggregate market value of the outstanding
Common Shares held by non-affiliates within the 60 days prior to this prospectus supplement based on the closing price of the Common Shares
on the Nasdaq on September 19, 2025, as calculated in accordance with General Instruction I.B.5. of Form F-3, was approximately $11.2
million. During the twelve calendar months immediately prior to and including the date of this prospectus supplement, we have not sold
any Common Shares pursuant to General Instruction I.B.5. of Form F-3.

We are an emerging growth company, as defined
in the Jumpstart Our Business Startups Act of 2012, and have elected to comply with certain reduced public company reporting requirements.

Investing in